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The association between hepatitis C virus (HCV) infection and type II mixed cryoglobulinemia (MCII) is well established, but
the role played by distinct HCV proteins and by speciﬁc components of the anti-HCV humoral immune response remains to be
clearly deﬁned. It is widely accepted that HCV drives the expansion of few B-cell clones expressing a restricted pool of selected
immunoglobulin variable (IgV) gene subfamilies frequently endowed with rheumatoid factor (RF) activity. Moreover, the same
IgV subfamilies are frequently observed in HCV-transformed malignant B-cell clones occasionally complicating MCII. In this
paper, we analyze both the humoral and viral counterparts at the basis of cryoglobulins production in HCV-induced MCII, with
particular attention reserved to the single IgV subfamilies most frequently involved.
1.Introduction
Mixed cryoglobulinemia (MC), an immune complex (IC)-
mediated systemic vasculitis mainly involving the small
blood vessels, has been observed in a wide variety of
diseases, including malignancies, chronic infections, and
systemic autoimmune disorders [1, 2]. In symptomatic MC,
the presence of cold-precipitable immunoglobulins (cryo-
globulins) is frequently associated with the development
of vascular, renal, and neurological lesions [3–5]. The vast
majority (50–90%) of patients with symptomatic type II
mixed cryoglobulinemia (MCII), characterized by lympho-
proliferation and by the deposition of mono/oligoclonal
IgM antibodies (Abs) with rheumatoid factor (RF) activity
bound to oligo/polyclonal IgG, are infected with hepatitis C
virus (HCV) [6]. Consistently, more than 40% of chronically
HCV-infected patients present MCII, that in a relevant
number of patients (10–60%) will eventually develop in
symptomatic cryoglobulinemia [7, 8].
It has been demonstrated that antiviral treatment sig-
niﬁcantly induces remission in HCV-associated MCII and
that this eﬀect is highly correlated with eﬀective suppression
of viral replication, supporting a direct role of HCV in
the pathogenesis of this lymphoproliferative disorder [9].
Furthermore, MC should not be considered an in situ or
occult B-cell lymphoma, as evidences indicate that its B-cell
clonal expansion does not still display the molecular features
of a true neoplastic process [10]. As a matter of fact, in
more than 50% of symptomatic patients the clinical course is
relatively benign, but 5–10% of patients with cryoglobuline-
mic vasculitis develop B-cell malignancies, in particular B-
cell non-Hodgkin lymphomas (B-NHL), as compared with
0.2–2.6% of the overall HCV-infected population [11–15].
A possible role of chronic immune stimulation associated
with persistent infection in the pathogenesis of these malig-
nancies has been hypothesized and further conﬁrmed by
the sequence analysis of tumor-related immunoglobulin (Ig)
gene rearrangements, evidencing a preferential use of the
same Ig heavy and light chain variable regions (VH and VL)
genes associated with anti-HCV response and with MCII
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In this paper, after reviewing the main viral features
associated with MCII, we will overview the main IgV gene
subfamilies described in patients with HCV-related MCII
and will evidence their correlation with the anti-HCV
humoral response and with the MCII-related neoplastic
complications.
2. The Liver asa Lymphoid Organ
It is well known that the liver is the main target organ of
HCV infection. Within the inﬂamed liver, particularly in the
earliest stages of the disease, there is an accumulation of
myeloid and lymphoid cells, including follicular dendritic
cells, T and B lymphocytes [19]. Local activation of these
cells is thought to play an essential role in perpetuating the
chronic inﬂammatory process and enhancing liver damage
[20]. Moreover, intrahepatic B-cell proliferation is often
associated with extrahepatic manifestations of HCV infec-
tion, including high serum levels of RF activity, cryoglobu-
lins, monoclonal gammopathy of undetermined signiﬁcance
(MGUS), and frank B-NHL, indicating that it has a direct
role in HCV-related systemic complications (Figure 1(a))
[21].
Immunohistochemical studies showed that T and B cells
frequently accumulate in the portal tracts and organize
follicle-like structures (foci), mainly consisting in B cells sur-
rounded by T-cell zones at the periphery. Within these foci
there are obvious germinal centres (GCs) where activation,
proliferation, diﬀerentiation, and maturation of B cells and
Ab production may occur similarly to lymphoid organs [22].
This process is rarely observed in patients with other types
of hepatitis and seems to contribute to the pathogenesis of
HCV immune-related disorders, as suggested by functional
and molecular analyses showing that these structures are
characterized by B-cell oligo/monoclonal expansion [23].
Indeed, these clonal expansions have been observed in
the liver of almost 50% of HCV-infected patients and,
less frequently, in their blood and bone marrow [21]. In
particular, Sansonno et al. observed a monoclonal pattern
only in HCV-infected patients with MC, while Magalini
et al. observed it both in MC and non-MC HCV-infected
patients, supporting the view that HCV per se is able to
derange the functions of the immune system [24, 25]. Fur-
thermore, isolated intrahepatic B lymphocytes were shown
to produce IgM molecules with RF activity, supporting the
intrahepatic origin of HCV-related autoimmune processes
[24, 26]. Interestingly, these intrahepatic focus-forming B
cells frequently express a restricted repertoire of VH and
VL subfamily genes, as discussed more in detail below.
Each single focus may derive from a single B cell, with the
result that distinct foci contain unrelated B-cell clones with
single-antigen (Ag) speciﬁcity (Figure 1(a)) [27]. Although
continuous viral antigenic stimulation is probably the main
factor determining the formation of intrahepatic GCs in
HCV-infected patients, the reason why, diﬀerently from
other hepatotropic viruses, HCV preferentially induces their
formation in the liver is currently uncertain. It might
be related to the unique virological properties of HCV,
including preferential induction of an autoreactive humoral
immune response.
Taken together, these observations suggest that, during
HCV infection, the liver acts as an important secondary
lymphoid organ where autoimmune processes may originate
(Table 1).Themainviralfactorsandthespeciﬁccomponents
of the anti-HCV humoral response involved in this process
will be reviewed in the following paragraphs.
3.HCVProteinsandBCells
HCV is an enveloped, positive-stranded RNA virus, charac-
terized by an extreme variability, even within a single host.
On the basis of some conserved regions it can be divided
in seven genotypes and numerous subtypes [28, 29]. All
HCV genotypes have been associated to MCII, although
several reports describe its higher prevalence among patients
infected with genotypes 1 and 2a [19, 24, 30–34]. However,
the diﬀerences in the geographical distribution of HCV
genotypes may bias this apparent correlation.
HCV genome is approximately 9600 nucleotides long
and encodes a polyprotein precursor of about 3000
aminoacids.Itiscleavedbyviralandhostproteases,resulting
in a series of structural (core, E1 and E2) and nonstructural
proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B)
[35].SomeHCVproteinshavebeendemonstratedtodirectly
activate important proinﬂammatory cascades in monocyte
and T cells. This activation may serve to lower activation
threshold thus enhancing cellular response to Ags, including
auto-Ags [36]. This may provide B cells with a pro-
inﬂammatory environment and a myriad of costimulatory
signals promoting clonal expansion. Moreover, sequence
data on BCR, the presence of HCV Ags in the cryoprecipi-
tates,andareported correlation between HCV viral loadand
clinical manifestations of cryoglobulinemia in some patients
support the model of an Ag-driven origin for HCV-related
lymphoproliferative disorders [30]. In this paragraph we
investigate this last point with particular attention to the
diﬀerent HCV proteins possibly involved.
3.1. Core Protein. Several reports describe the presence of
HCV RNA and HCV proteins in the cryoprecipitate of
patients with HCV-related MCII. In particular, the core
is supposed to be the most involved viral protein in
cryocrit formation, as demonstrated in the skin and renal
tissues of HCV-infected patients with MCII-associated active
vasculitis and nephropathy, respectively [37]. Nonenveloped
core protein is overproduced during virogenesis, and in
MCII patients its plasmatic levels have been correlated to
cryoglobulinemia-associated symptoms [37, 38]. Indeed, it
hasbeendemonstratedthatHCVcoreproteinparticipatesin
the formation of immune complexes (ICs) and suppresses T-
cell response by interacting with the globular domain of C1q
complement receptor (gC1qR) (Figure 1(b)) [39, 40]. This
interaction may play a key role in determining complement
activation, a crucial interdependent regulator of the size and
solubility of immune aggregates [41].
Sansonno et al. demonstrated the presence of high levels
of HCV core protein in the cryoprecipitates of patients withClinical and Developmental Immunology 3
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Figure 1: Proposed etiopathogenetic mechanisms involved in the origin of HCV-induced MCII. (a) Direct involvement of HCV infection
and of speciﬁc HCV Ags in the emergence and maintenance of B-cell expansions, more frequently occurring in the liver and mostly
involvingRF-producingBcells.ThisB-cellrepertoireisthereforelimitedandlikelycodedbyfewgermlinegenes.Theseclonalexpansionsare
invariably associated with extrahepatic manifestations, including high serum levels of polyclonal rheumatoid factor activity, cryoglobulins,
monoclonal gammopathy of undetermined signiﬁcance (MGUS), and eventually frank B-cell non-Hodgkin lymphoma (B-NHL). (b) The
wide expression of gC1qR on the surface of blood cells, like neutrophil granulocytes, as well as of endothelial cells favors their speciﬁc
binding to immune complexes containing HCV core protein and may determine their cold precipitation. Alternatively, IgM molecules
are good acceptors of C1q, whose binding site is on their Fc portion and, if endowed with RF activity, may precipitate in presence of
IgG molecules with speciﬁc anticore activity. (c) HCV/E2- and HCV/NS3-induced proliferation and expansion of B-cell clones producing
cross-reactive Ig recognizing structures shared between these Ags and discrete Ig regions (i.e., Fc or IgV domains). (d) HCV might initiate a
multistageprocessoflymphomagenesisbyreplicatinginlymphoidcellsandexpressingproteinsthatassociatewithhostcell-encodedtumor-
suppressing proteins, thereby abrogating their cell-cycle checkpoint functions and predisposing the cell to genetic instability. Alternatively,
HCV/E2 binding to CD81, as part of the CD19/CD21/CD81, might provide a strong proliferation signal. Moreover, HCV/E2 could behave
as a B-cell super-Ag and directly stimulate proliferation and oligo/monoclonal expansion through its direct binding to BCRs encoded by
speciﬁc IgV subfamilies.
MCII [42]. These cold-insoluble precipitates included poly-
clonal IgG and monoclonal IgM molecules with RF activity.
In particular, the polyclonal IgG component showed speciﬁc
reactivity against HCV core protein and, in turn, was linked
through its Fc portion to IgM with RF activity. Importantly,
cryoprecipitation was directly correlated with anticore IgG
concentration in the cryoprecipitate, thus inferring that its
production is dependent on their selective binding to the Ag
in the presence of IgM molecules with RF activity. Thus, IgM
RF acts as an incomplete cryoglobulin, precipitating at low
temperature, probably following a conformational change
induced by their binding to IgG with anti-core reactivity.
In the same report, the above-described HCV core
protein interaction with the gC1qR was proposed as another
pathogenetic mechanism, making T cells unable to suppress
RF producing B-cell clones generated by chronic antigenic
challenge. The presence of gC1qR on the surface of both
circulating blood cells and endothelial cells may favor their
speciﬁc binding to HCV core protein-containing ICs [5, 43].
Moreover, IgM molecules are good acceptors of C1q and
indeed can favour indirect binding of HCV core protein to
endothelial cell surface (Figure 1(b)) [44].
Finally, HCV core protein has also been shown to
promote immortalization in diﬀerent cell lines, as well as4 Clinical and Developmental Immunology
Table 1: Schematic representation of viral and humoral factors implicated in the instauration of HCV-related MCII and B-NHL.
Implicated factors Associated mechanisms References
HCV proteins
Core
(i) Complement activation
(ii) Cryoprecipitation
(iii) ↓ T cell response
[37, 39, 41–43, 45]
E2
(i) Molecular mimicry of IgV domain
(ii) Induction of RF
(iii) Proliferation and transformation signals
following interaction with CD81/BCR
(iv) Super-Ag?
[46, 47, 52–59]
NS3 (i) Molecular mimicry of IgG-Fc domain
(ii) Oncogenesis [69, 71]
IgV subfamilies
VH1-69
(i) Expansion of CD5+ B cells?
(ii) WA with RF activity
(iii) Expansion of natural IgM
expressing B cells
[52, 55, 76, 78, 79,
97–99]
Heavy chains VH4-34 Naturally autoreactive [79]
VH4-59, VH3-7,
VH3-21, VH3-23,
VH3-48 and VH3-30
Mono/oligoclonal expansion following HCV
infection
[75, 77, 100–102]
Light chains Vκ3-15 [80]
Vκ3-20 WA with RF activity [77, 80, 97, 103,
104]
being capable of blocking c-myc induced apoptosis and
indeed could have a direct role in the pathogenesis of HCV-
related lymphomas [45].
3.2. E2 Envelope Glycoprotein. HCV/E2 envelope glycopro-
tein is another viral protein possibly involved in the devel-
opment of HCV-related lymphoproliferative disorders [46].
A hint suggesting HCV/E2 role comes from the reported
molecular mimicry of its N-terminal hypervariable region
(HVR1) with some conserved motifs in selected human Ig
variable domains, as well as with the T-cell receptor (TCR)
alpha and beta chains (Figure 1(c)) [47]. This molecular
mimicry would make anti-HVR1 Abs potentially capable
of cross-reacting with other Abs or with TCR. Indeed, the
expression of proteins structurally similar to host defense
proteins and immunomodulators is an important immune-
evasion strategy leading to persistence, already described for
other viruses [48–51]. Conﬁrming this, Ferri et al. demon-
strated a low pattern of HVR1 mutations in HCV-positive
patients with MCII and presenting a monoclonal IgM
expansion with RF activity [52]. This low variability in the
main target of anti-HCV humoral response was interpreted
as a clear sign of impaired response, as already observed
in agammaglobulinemia or in otherwise immunosuppressed
patients [53, 54]. Interestingly, a direct correlation has been
observed between the degree of similarity of HCV/E2 HVR1
to Ig and TCR molecules and the degree of immune escape
and persistence in humans and experimentally infected
chimpanzees [47]. This indicates that variation in HVR1
sequenceisnotonlycorrelatedwithescapefromneutralizing
Abs but also to an improvement in Ig similarity consistent
with a model of immune evasion through mimicry. Overall,
this mimicry could determine a chronic stimulation induced
alsobyself-Ags,thusleadingtotheHCV-relatedlymphopro-
liferative disorders.
Asamatteroffact,inHCV-associatedB-NHL,malignant
monoclonal B cells often secrete IgM endowed with RF
activity which feature high sequence homology with anti-
HCV/E2 Abs [55]. Thus, it has been suggested that these
forms of B-NHL may originate from monoclonal prolifer-
ation of RF-secreting B cells stimulated as reported above
(Figure 1(c)) [52]. Consistently with this observation, Igs
cloned from a patient with an HCV-associated B-NHL were
shown to bind to HCV/E2 [56].
Finally, it has been postulated that HCV may also exert a
directstimulatingactivityonBcellsfollowingHCV/E2inter-
action with the cellular receptor CD81 during the viral par-
ticle internalization [57, 58]. In fact, the CD81 tetraspanin
on B-cell surface may provide a strong stimulatory signal if
activatedaspartofacomplex(CD19/CD21/CD81complex),
together with the activation of BCRs belonging to restricted
VH subfamilies and recognizing HCV/E2. Indeed, the ability
of E2 to directly engage CD81 in addition to the binding
of speciﬁc anti-HCV/E2 BCRs may create a powerful stim-
ulatory signal, promoting proliferation (Figure 1(d)). As a
possible consequence of this mechanism, CD81 is upregu-
lated in HCV-infected patients, with a further upregulation
inpatientswithMCII.However,conﬂictingresultshavebeen
published showing CD81 downregulation, whereas CD19
receptor was upregulated on peripheral B lymphocytes inClinical and Developmental Immunology 5
HCV-infected patients with MCII or B-NHL. In addition,
HCV/E2 binding to CD81 induces double-strand DNA
breaks and hypermutation, speciﬁcally in the VH gene of
B cells. This process was demonstrated to be dependent
on activation-induced cytidine deaminase and related to an
increase in the production of TNF-alpha [59, 60].
3.3. NS3 Protein. It is known that NS3 can induce an
important humoral and cellular immune response [61–
68]. A possible role of NS3 in inducing autoreactive Abs
through molecular mimicry has been hypothesized [69]. In
particular, IgM reacting against the NS3 helicase domain is
presentinthecryoprecipitateofallchronicallyHCV-infected
patients with a bone marrow monoclonal B-cell pattern
and of a consistent portion (36%) of HCV-related MCII
patients [69]. These IgM Abs recognize epitopes located
within a region (1238–1279), previously indicated as one of
the two immunodominant regions for B cells on NS3 (1250–
1334 and 1359–1449). Importantly, these IgM Abs show also
reactivity against human IgG and in particular against a
unique peptide (Fc345–355) corresponding to the IgG CH3
domain (Figure 1(c)).
On the other hand, the region of NS3 encompassing
residues 1406–1415 has been demonstrated to be also a
CD8+ T cell epitope [70].
The possible role of HCV/NS3 protein in the patho-
genesis of HCV-associated MC is also suggested by another
studyevidencingNS3depositsinthekidneyofviremicHCV-
positive patients with membranoproliferative glomeru-
lonephritis associated with cryoglobulinemia and presenting
a mild polyclonal B lymphocytosis [71].
In addition, NS3 has been demonstrated to promote
oncogenic transformation and to interact with p53 and
interfere with apoptosis, thus contributing singularly or
synergistically with the HCV/E2 and core proteins to the
development of HCV-related lymphomas [11, 72–74].
4.BiasedIgVSubfamilyUse and
Lymphoproliferation
As evidenced above, understanding the nature of the B
cell-stimulating Ag resulted to be extremely diﬃcult. One
reason relates to the diﬃculty in isolating expanded cells
that are mostly conﬁned to restricted areas of the liver or of
the bone marrow. Another reason relates to the complexity
of analyzing the BCR speciﬁcity of oligoclonal expanded
cells, which are present at low concentrations among tissue
resident, nonspeciﬁc, B-cell populations. A further reason
is the diﬃculty in obtaining reliable information from
comparing the sequences of autoreactive BCRs or Abs with
those of BCRs or Abs of known speciﬁcity.
Some data could be obtained from the cloning of the VH
and VL genes into an expression vector and from the testing
of their biological activity. As an example, in several studies
the use of phage display technology allowed the selection of
distinct autoreactive Abs which were further characterized
in terms of Ag speciﬁcity and biological activity [75]. These
studies demonstrated that the VH and VL sequences of
the cryoprecipitable monoclonal IgM match those of the
IgV genes of monoclonal B cells isolated from patients
with MCII [55, 76]. This conﬁrms that in patients with an
established monoclonal pattern, the IgM component of ICs
represents the circulating counterpart of the BCR expressed
on the surface of expanded B cells and, therefore, can be
exploitedtoidentifytheputativeAginvolvedininducingand
maintaining B-cell activation.
Interestingly, several other studies demonstrated the
recruitment of selected IgV gene subfamilies, the presence
of IgV genes mutations compatible with a GC or post-GC
derivation, a replacement/silent mutation ratio consistent
with the maintenance of a functional structure of the BCR,
and the presence of intraclonal heterogeneity evidencing
an ongoing Ag-induced maturation [21, 24, 55, 76–80].
Conceivably, the similarity in the structure of the variable
BCR region and the restricted recruitment of certain IgV
subfamilies, both for heavy and light chains, may account
for selection of B cells expressing speciﬁc and common
reactivity.
In this paragraph we will review the V gene subfamilies
most frequently observed in HCV-related lymphoprolifera-
tive disorders.
4.1. VH1-69
4.1.1. Molecular Characteristics of VH1-69 Subfamily-Derived
Abs. Approximately 1.7% of peripheral blood B cells of
healthy individuals express the distal VH1-69 gene, as
expected for a random use of the total repertoire of
functional VH gene regions [81]. Furthermore, this gene
segment is expressed in the restricted repertoire of fetal
liver B lymphocytes and is thought to be involved in
naturalimmunity[82,83].Althoughminimallyusedinadult
life, this VH subfamily is highly represented in anti-HCV
humoral immune response, particularly that directed against
the HCV/E2 glycoprotein [84–88].
Interestingly, this subfamily is highly represented also
in broadly neutralizing humoral responses directed against
other enveloped viruses, such as inﬂuenza viruses and
HIV [89–92]. In particular, several groups have described
the heterosubtypic activity of VH1-69-derived monoclonal
antibodies (mAbs) directed against the hemagglutinin (HA)
stem region of inﬂuenza A viruses [89, 90, 93, 94]. This
suggests the presence of a conserved motif in this Ab sub-
family determining the observed peculiar features. Indeed,
crystallizationstudiesdemonstratedthatthesemAbsinteract
with the Ag only through the VH1-69-derived heavy chain
CDR1 and CDR2 regions, but not with the CDR3 that
usually confers Ag speciﬁcity to an Ab [95]. In particular,
the distinct hydrophobic CDR2 loop encoded by VH1-69
may confer antiviral activity by binding to hydrophobic viral
targets [90]. Another peculiar feature of the anti-HA VH1-
69-derived mAbs was their extremely long CDR3 region
[90]. Interestingly, a very long CDR3 and high levels of
somatic mutations were also observed in VH1-69-derived
mAbs directed against other viruses, such as HIV [96].
Moreover, similar characteristics were observed also for anti-
protein Abs produced in the context of chronic systemic
autoimmune diseases [96]. Conversely, for HCV infection,6 Clinical and Developmental Immunology
a recent paper reported a shorter CDR3 length of the Ab
repertoire in people who spontaneously resolved an acute
HCV infection compared to healthy individuals and those
with chronically evolving HCV infection, and the authors
explain this diﬀerence suggesting a mobilization of the Ab
repertoire due to clonal selection [76].
4.1.2. VH1-69 and HCV-Related Cryoglobulinemia and Lym-
phomas. The VH1-69 germline gene is commonly reported
in monoclonal IgM observed in HCV-related lymphopro-
liferative disorders as well as in normal B cells responding
to the HCV/E2 viral antigen [52]. Furthermore, analysis of
this V region sequence in HCV-infected cryoglobulinemic
patients revealed that it undergoes somatic mutation, pre-
sumably during aﬃnity maturation. This observation has
corroborated the hypothesis that HCV-associated MCII and
lymphomas may originate in B cells responding to HCV/E2
glycoprotein, the most involved in stimulation of VH1-
69 expressing B cells [79]. Studying patients with HCV-
associated type II MC, Carbonari et al. reported that up
to 98% of their circulating B cells expressed the VH1-69
gene and that it was frequently associated with the Vκ3-20
light chain gene [78]. This pairing was also frequently found
among B-cell chronic lymphocytic leukemia (B-CLL) clones
[105] .I n d e e d ,i th a sb e e nd e s c r i b e dt h a tm o s tc o m m o n l y
the association of these two subfamilies forms the WA cross-
reactive idiotype (Id) endowed with RF activity [52, 97].
Moreover,ithasbeenobservedthattheVH1-69expressionis
frequently associated with DH3-22 and JH4 rearrangements,
especially in patients with HCV-associated MCII [77, 98].
Preferential use of this gene has also been seen in 10–
20%ofpatientswithCD5+B-CLL,andpolyclonalactivation
and expansion of CD5+ B cells occur during interaction
betweenHCVandlymphocytesandareassociatedwithHCV
infectionandHCV-relatedMCII[19].Thecirculatinginnate
CD5+ cells are in fact believed to be equivalent to murine
B-1 cells, which have restricted receptor gene segment usage
and are primary source of auto-Abs (IgM). But, in this
regard, there are conﬂicting data, as other groups reported
no correlation between the increase of CD5+ B cells and
the presence of cryoprecipitate or RF in patients with HCV-
related lymphoproliferative disease [77, 80, 99, 100].
Furthermore, it has been observed that the majority of
VH1-69-expressing B cells in HCV positive patients had
a memory phenotype and express modestly somatically
mutated IgM, indicating that a clonal population of memory
VH1-69 expressing B cells progressively invades the circu-
lating B-cell compartment of patients with HCV-associated
MCII [99]. It has also been reported that the peripheral B-
cell repertoire of HCV patients may be represented almost
completely by VH1-69 monoclonal B cells [78, 106]. More-
over, some of these clones have CDR3 sequences identical to
RF IgMs isolated from patients with MALT neoplasms, with
MCII-associated splenic lymphoma, and with leukaemia-
like B-cell monoclonal expansion [78, 106]. Thus, originally
nonneoplastic VH1-69 B cells responding to Ag stimulation
could evade the homeostatic mechanisms that regulate the
Ag-driven clonal expansion, and subsequent genetic events
may cause further escape from control and lead to absolute
lymphocytosis.
Finally, recent evidences suggest that somatic hypermu-
tation, as well as class switching, may signiﬁcantly alter
the germline-determined original BCR reactivity [107, 108].
This may explain why VH1-69-derived IgG Abs are often
endowed with a broadly neutralizing anti-HCV activity,
whilst their IgM counterpart may feature autoreactive activ-
ity.Inthisregard,Racanellietal.identiﬁedthepauciclonality
of the peripheral memory B-cell population as a distin-
guishing feature of patients who spontaneously resolved an
acute HCV infection compared to those chronically evolving
HCV infection. This ﬁnding, also observed in patients
with preneoplastic HCV-associated lymphoproliferative dis-
orders, suggests that the B-cell clones potentially involved in
clearance of the virus may also be originally more prone to
feature autoimmune characteristics and more susceptible to
undergo abnormal expansion [76].
4.2. Other VH Subfamilies. B cell mono/oligoclonal expan-
sion of clones expressing VH subfamily gene segments other
than VH1-69, such as VH3-7, VH3-21, VH3-23, VH3-30,
VH4-34, VH3-48, and VH4-59, seems to be implicated in
HCV-related lymphoproliferative disorders [75, 77, 100].
Moreover, as in the case of VH1-69, monoclonal expansion
of B-cell clones expressing most of these VH subfamilies is a
common feature of a wide variety of autoimmune disorders
and lymphomas [75, 100, 101, 108].
4.2.1. VH3-21 and VH3-23. Our group previously reported
that the biased VH1-69 gene use in anti-HCV/E2 response
may selectively expand B-cell clones reacting against this
speciﬁc VH subfamily. In particular, it has been observed
thattheimmunerepertoireofapatientwithHCV-associated
MCII contains IgM clones able to react speciﬁcally against
anti-HCV/E2 Abs belonging to VH1-69 subfamily derived
from the same patient. Indeed, we found that 61% of IgMs
reactive to anti-HCV/E2 VH1-69-Fab fragments belonged
only to two VH subfamilies, VH3-23 (39%) and VH3-
21 (22%), that are frequently described in autoimmune
disorders [75, 101].
Furthermore, the mutational pattern of selected anti-
HCV/E2 IgMs showed that almost all clones featured a
high homology to the germline. More in details, diﬀerently
from VH3-21 subfamily, VH3-23 clones did not feature
polyreactivitybutshowedabindingbiastowardtheVH1-69-
derived IgG1 Fabs. These data suggest that VH3-23 IgM may
be naturally prone to recognize speciﬁc VH regions within
the VH1-69 subfamilies [75, 102].
Overall, the HCV/E2-driven stimulation of the immune
system may cause the expansion of speciﬁc B cells expressing
VH1-69-derived Abs recognized by some natural IgM Ab
subfamilies. This could lead to the formation of circulating
ICs, and the cross-linking of BCR by auto-Abs may allow a
chronic activation and a clonal expansion of anti-HCV/E2 B
cells.
4.2.2. VH4-34. The VH4-34 gene is used in about 5% of
healthy adult B lymphocytes and is frequently found inClinical and Developmental Immunology 7
diﬀuse large-cell lymphoma, primary central nervous system
lymphoma, B-CLL, and several autoimmune disorders [79].
Furthermore, it is well known that, independently from
the associated DH and JH gene segments, as well as from the
subfamilyandisotypeofthepairedlightchain,theVH4-34is
a naturally autoreactive subfamily. Interestingly, the VH4-34
gene is found in virtually all cases of cold agglutinin disease,
where the red blood cell I/I Ags bind to the FR1 domain
of selected Ig subfamilies, including VH4-34, with a minor
involvementoftheCDR3region[109].Indeed,therestricted
usage of VH genes and the binding outside the CDRs
are characteristics of B-cell super-Ags that are supposed to
directly activate B cells [110]. As previously mentioned, this
could be the case of the HCV/E2 glycoprotein, due to its
ability to stimulate the expansion of a restricted set of VH
and VL subfamily expressing B cells. Moreover, as previously
described, it directly provides a strong proliferation signal
to B cells through its interaction with CD81 as part of the
BCR complex. A similar behavior has also been described
for staphylococcal enterotoxins A and D, that function as
human B super-Ags rescuing B cell-expressing VH3 and
VH4 (including VH4-34) genes inducing cell survival in in
vitro experiments, and has been suggested also for gp120 of
HIV [96, 111]. Moreover, certain portions of the FRs seem
to be important for super-Ag binding, and these would be
preserved in a super-Ag selective pressure [109].
Therefore, the high frequency of the VH4-34 gene usage
and the intrinsic molecular features of its FR and CDR
domains suggest a possible role of yet unknown B-cell super-
Ag in driving HCV-related lymphoproliferative disorders
[79].
4.3. VL Subfamilies. In the majority of clonal B-cell expan-
sions following HCV infection there is a major involvement
of Vκ-expressing B cells, as demonstrated by the highly
skewed κ/λ ratio and as corroborated by the usage of the
Vκ genes belonging to restricted subfamilies, as Vκ3-15
and Vκ3-20 [80]. As previously mentioned, the Vκ3-20
germline gene expression during HCV humoral immune
responseisfrequentlyassociatedwiththeVH1-69expression
in the context of HCV-associated MCII and lymphomas
[77, 80, 103].
Giving this restricted Vκ usage in HCV-positive subjects
with a related MCII as well as in those evolving in a B-NHL,
somereportssuggestanimmuneattacktargetedonidiotypic
determinants, as a possible passive or active immunotherapy
for HCV-related autoimmune diseases and B-cell lym-
phomas [104]. In particular, De Re et al. after immunization
of an experimental model with a VH4-59/Vκ3-20 scFv mAb,
cloned from a patient with a HCV-related MCII and B-
NHL, demonstrated the possible induction of anti-Id Abs
directed against conserved Vκ epitopes. This ﬁnding opens
to possibilities of a potential therapeutic application of Abs
reactive with shared Id for patients with HCV-associated
B-cell lymphoproliferative diseases, obviating the need to
produceananti-IdAbortouseadiﬀerentIdvaccineforeach
patient[103].Consistently,thisapproachhasbeenappliedin
some types of B-cell tumors and some autoimmune diseases
[112].
5. Conclusions
Several viruses are involved in the development of systemic
autoimmune-related damage. Over the last few years several
studies have ﬁrmly demonstrated the close interplay between
a primarily hepatotropic virus, such as HCV, and B cells and
the role of this interaction in the occurrence of HCV-related
autoimmune preneoplastic lymphoproliferative disorders, as
MCII. The HCV-induced stimulation of distinct speciﬁc B-
cell clones expressing speciﬁc BCRs, derived from a limited
numbers of V gene subfamilies, clearly underlines the role
of speciﬁc HCV Ags in the initiation of this pathogenetic
mechanism. However, there are still many dark areas left,
such as the molecular factors determining the breaking of
“self tolerance” and those leading from the clonal expansion
of a limited number of HCV-speciﬁc clones to the neoplastic
immortalization of some of them.
Overall, these mechanisms may be seen as escape strate-
gies put forth by HCV to evade the immune response in
the course of a persistent infection [47, 113]. This point of
view, as well as the approaches followed in the study of HCV-
related autoimmune disorders, may be important also in the
evaluationofotherautoimmunediseasesnotyetrelatedwith
an infectious etiology or associated to a given pathogen. The
study of the systemic and local B-cell repertoire in the course
ofdiseases,assystemicsclerosis,multiplesclerosis,orspeciﬁc
clinical forms of atherosclerosis, and its comparison with
the speciﬁc V gene repertoire induced by a given pathogen
may be a new way for investigating their real causes opening
new doors on the comprehension of their pathogenesis
[114–119].
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